A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA)
This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab compared with a matching placebo in combination with standard of care in hospitalized patients with severe COVID-19 pneumonia.
|Imperial PI||Dr Nichola Cooper|
|Trial Sponsor||Hoffmann-La Roche|
|Study status||Closed to recruitment|